Total Revenue

+5.4% (from 78,025k to 82,280k USD)

Total Revenue increased mainly due to robust growth in the international segment (+23%) and strong sales revenue growth (+8.6%), which more than offset the slight domestic decline (-3.3%). This shift builds on the performance trends seen in previous periods, where international business-to-business sales proved to be a key leverage point for revenue expansion. " " " "

U.S. Revenue

-3.3% (from 51.99m to 50.30m USD)

U.S. Revenue declined slightly, reflecting challenges in the domestic market such as saturation or competitive pressures that were also observed in earlier periods. This underperformance contrasts with international gains and indicates that domestic operational challenges persist, similar to previous periods' issues in direct-to-consumer or rental segments. " "

Non-U.S. Revenue

+23% (from 26.04m to 31.99m USD)

Non-U.S. Revenue surged, driven by significantly higher international business-to-business sales. The increase aligns with trends from earlier periods where demand from European markets and new international partners played a key role, even though Europe’s revenue share slightly declined. " "

Sales Revenue

+8.6% (from 63,095k to 68,470k USD)

Sales Revenue grew as a result of increased orders and higher unit sales, indicating improved operational performance. This reflects an ongoing positive trend from previous periods where strengthening of business-to-business channels substantially boosted overall sales revenue. " "

Rental Revenue

-7.4%

Rental Revenue fell by around 7.4%, continuing the trend from previous periods where a higher mix of lower-billing rates (due to private-payor reimbursements) negatively impacted this channel. The decline underscores persistent structural challenges in the rental segment that have not yet been resolved. " "

Operating Loss

Improved by ~53% (narrowing from 16,274k to 7,656k USD)

The dramatic reduction in Operating Loss is attributed to tighter cost controls and improved expense management. Initiatives implemented in previous periods, such as operational efficiencies and targeted reductions across key expense categories, have yielded significant improvements in Q1 2025. " "

Net Loss

Improved by ~57% (narrowing from 14,578k to 6,174k USD)

The marked reduction in Net Loss resulted from increased total and sales revenue combined with lower operating costs. This positive momentum builds on strategies from previous periods—such as cost-cutting measures and revenue mix improvements—that have steadily reduced the net loss over time. " "

Revenue

Q1 2025

$79 million to $81 million, reflecting 1% to 4% reported growth "

no guidance provided

no current guidance

Revenue

FY 2025

$352 million to $355 million, reflecting 5% to 6% reported growth "

no guidance provided

no current guidance

Gross Margins

FY 2025

43% to 45% " "

no guidance provided

no current guidance

Adjusted EBITDA

FY 2025

Approaching adjusted EBITDA breakeven "

no guidance provided

no current guidance

Rental Revenue Dynamics & Margin Volatility

Earlier quarters (Q2–Q4 2024) reported steeper revenue declines (e.g., 16.5% drop in Q4) and significant gross margin compression due to a mix shift to private payers " " "

Q1 2025 saw a lower revenue decline of 7.5% with gross margin decline of 33 bps; management noted that the negative dynamics are leveling off and sequential revenue improvements are emerging " "

Improving sentiment: Although challenges persist, the rate of decline has moderated, suggesting stabilization.

Cost Management & Operating Expense Adjustments

Q2 2024 mentioned increased expenses driven by personnel costs and high advertising spending; Q3 and Q4 focused on cost reductions with operating expense cuts and EBITDA improvements " " "

Q1 2025 reported a notable operating expense reduction of 13.1%, a pullback in G&A and R&D, and achieved positive adjusted EBITDA performance " "

Accelerating efficiency: Consistent focus on cost management with stronger improvements in Q1 2025.

B2B Growth & Partnership Expansion

Q2–Q4 2024 highlighted robust domestic and international revenue growth in B2B channels and introduced the strategic Yuwell Medical partnership in Q4; recurring steady volume increases " " " "

Q1 2025 confirmed continued strong B2B growth with domestic revenue up 29.9%, international up 22.9%, significant unit growth, and the finalized Yuwell Medical collaboration " " " "

Sustained momentum: Consistent robust growth with strategic partnership expansion, reinforcing a positive outlook.

Sales Force Restructuring & DTC Channel Optimization

Across Q2–Q4 2024, the focus was on downsizing the DTC team for profitability, resulting in short-term revenue declines but an emphasis on improved revenue per rep and long-term patient-first initiatives " " " " " "

Q1 2025 reiterated the optimized, smaller DTC sales force; DTC revenue declined further but was paired with a patient-first initiative that is expected to drive future improvement " " " "

Cautiously optimistic: Consistent restructuring efforts with short-term revenue headwinds, yet positive long‑term performance expectations.

Regulatory & Reimbursement Uncertainty (Simeox Focus)

Q2 and Q3 2024 discussed progress toward FDA clearance and building clinical evidence; Q4 2024 provided detailed steps for CMS and private payer engagement, highlighting uncertainty and a cautious approach " " " "

Q1 2025 reported ongoing efforts on reimbursement and a limited commercial release but provided no material updates "

Persistent uncertainty: Steady focus on regulatory progress with no major breakthrough, maintaining a cautious tone.

New Product Pipeline & Innovation (Rove Series)

Q2–Q4 2024 emphasized the upcoming and then launched Rove 4, highlighting its lightweight design, extended battery life, and digital health integrations as key innovations " " "

Q1 2025 did not specifically mention the Rove Series, with the focus shifting to other innovation areas (e.g. Simeox and digital health updates) "

Shift in focus: Previously active discussion on Rove Series is absent, possibly indicating a pause or transition in messaging.

Seasonality & Revenue Cadence Challenges

Q2 2024 noted headwinds from an election (rising ad costs and fewer leads) while Q4 2024 reaffirmed that Q1 and Q4 are traditionally lower quarters due to seasonality " "

Q1 2025 continued to address seasonality issues in the DTC channel, citing tough year-over-year comparisons in the first half with expectations for improvement in the latter half " "

Consistent challenge: Recurring seasonal patterns remain, with recognition of lower performance early in the year and anticipated recovery later.

Expanding Upstream Hospital Channel

Q2 2024 featured a detailed discussion on a pilot program to capture patients immediately post-hospital discharge; Q3 2024 mentioned progress on the hospital pilot program; Q4 2024 did not address it further " "

Q1 2025 did not mention the hospital channel expansion at all

Deprioritized: Previously discussed in Q2 (and briefly in Q3), its absence in Q1 suggests a possible shift away or a pause in emphasis.

Billing Process Volatility

Q4 2024 provided detailed commentary on lower average billing rates and a steep decline in gross margin due to billing volatility "

Q1 2025 revisited billing challenges with management noting the mix shift impact, but also mentioned that the dynamics are beginning to level off "

Slight recovery: A recurring challenge that appears to be stabilizing, though issues with payer mix remain impactful.